SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Mutation C785T

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

1 Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)

The purpose of this study is: - To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy. - To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment. - To evaluate whether thyroid status at the time of remission is associated with subsequent relapse rate. - To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the serotonin transporter promoter gene in depression (5-HTTLRP).

NCT01299337 Depression Drug: T3
MeSH:Depression

The DI-C785T allele will be associated with lower T3 levels at baseline and faster treatment response. --- C785T ---

Primary Outcomes

Measure: To determine if people get better faster and stay better longer using T3 as adjunct to ECT.

Time: Phase A and Phase B

HPO Nodes